What Dolgosin Treats: Main Uses and Benefits

Dolgosin is commonly used in the symptomatic management of conditions characterized by periods of heightened symptoms related to inflammatory or irritative states. It is applied across domains where additional symptomatic support is needed for both chronic and acute manifestations.

The medication is generally applied when patients experience symptom clusters that include pain, swelling, and fever. It is used to help with conditions like rheumatoid arthritis, osteoarthritis, acute gout attacks, primary dysmenorrhea (menstrual cramps), and pain following musculoskeletal trauma such as sprains. This medicine is commonly used to help address these pronounced symptoms:

“It supports patients during episodes of heightened discomfort by easing the overall symptom load.”

The therapeutic benefit may assist with maintaining functional stability and contributes to easing the overall symptom burden when symptoms interfere with routine activities.

---

Quick Fact: Support for Symptom Management

Property	Description
Primary Focus	Symptomatic management of pain and inflammation
Symptom Axes	Physical discomfort, systemic imbalance, functional strain
Typical Context	Acute episodes, chronic joint conditions, post-trauma
Patient Benefit	Supports coping and general well-being during symptomatic phases

Regulatory References

1. NIH LiverTox overview of Ketoprofen indications

Who can and cannot use Dolgosin?

Eligibility to use Dolgosin (Ketoprofen) is defined by official regulatory documents that specify populations for whom the medicine is contraindicated or subject to severe restrictions.

Classification	Description
Populations for whom use is allowed	Adults (generally 18 years and older) who do not have any listed contraindications or specific risk factors requiring restricted use.
Populations for whom use is not recommended	Breastfeeding women; women attempting to conceive.
Populations for whom use is contraindicated	Patients with known hypersensitivity to the drug, aspirin, or other NSAIDs (e.g., aspirin-sensitive asthma). Patients with active gastrointestinal bleeding or severe, uncontrolled heart failure. Patients undergoing Coronary Artery Bypass Graft (CABG) surgery.

Age-Related Eligibility Rules

• Pediatric (< 18 years): Safety and efficacy have not been established; use is not approved or recommended in this population.
• Older Adults (ge 65 years): Use requires caution and close monitoring due to increased risk of serious gastrointestinal and cardiovascular events.

Physiological and Comorbidity Restrictions

• Pregnancy (Third Trimester, ge 30 weeks): Contraindicated. Use is limited between 20 and 30 weeks gestation.
• Organ Function: Use is prohibited in cases of severe renal impairment (creatinine clearance < 30 mL/min) and requires careful monitoring in patients with non-severe liver disease or kidney impairment.

Interactions with other medicines and products

The official regulatory profile for Dolgosin (Ketoprofen) mandates specific restrictions on co-administration with several medicinal products and substances, based on documented interaction patterns.

Contraindicated and Risk-Heightening Combinations

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including high-dose salicylates and COX-2 inhibitors, is formally not recommended due to a significantly increased risk of serious gastrointestinal adverse events. The medicine is also contraindicated for treating perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) Surgery. This medicine increases the risk of bleeding when taken with Oral Anticoagulants (such as Warfarin) and Anti-platelet Agents, a pharmacodynamic interaction. Combining Dolgosin with Selective Serotonin Reuptake Inhibitors (SSRIs) also increases the potential for gastrointestinal bleeding.

Pharmacokinetic and Organ System Effects

Dolgosin interacts with Diuretics, ACE Inhibitors, and Angiotensin II Receptor Blockers (ARBs), diminishing their antihypertensive effect and significantly increasing the risk of worsening renal function. The plasma concentrations of Lithium and Methotrexate (at high doses) are officially documented to increase when co-administered due to reduced renal clearance. For Methotrexate, the regulatory label specifies it should not be administered less than 12 hours before the start or after the end of Ketoprofen treatment. Co-administration with Alcohol increases the risk of serious gastrointestinal events. Elderly patients are noted in labels as having a heightened risk of interaction-related renal injury.

The mechanism of Dolgosin is defined by the action of its single active ingredient, Ketoprofen, within the pathways that generate chemical mediators of nociception and the inflammatory response. The core molecular interaction involves the non-selective, competitive inhibition of the Cyclooxygenase (COX) enzyme system (both COX-1 and COX-2 isoforms).

By blocking these enzymes, the drug prevents the conversion of arachidonic acid into prostaglandins, thereby interrupting a key molecular cascade. This leads to the modulation of signaling dynamics in affected tissues. Peripherally, this action reduces the chemical sensitization of peripheral sensory fibers (nociceptors), which modulates the transmission of afferent sensory signals.

Simultaneously, the decrease in prostaglandin levels attenuates local vasodilation and increased capillary permeability, influencing the resulting extravasation and tissue edema formation. Centrally, the molecule suppresses prostaglandin synthesis within the hypothalamus, an adjustment that modulates the thermoregulatory set point, thereby enabling the physiological system to initiate heat dissipation mechanisms.

How Dolgosin is Used: Administration Guidelines

Dolgosin (Ketoprofen) is administered according to protocols designed to ensure appropriate systemic delivery. These instructions outline the routes, frequencies, and population-specific modifications associated with its use.

Administration and Dosage

The medicine is primarily administered through the oral route as capsules or tablets for systemic effect. Administration can also include topical forms (gel) for localized use. The available oral forms include Immediate-Release (IR) capsules (e.g., 25 mg to 75 mg) and Extended-Release (ER) forms (200 mg), which are to be swallowed whole and not crushed or chewed.

Standard Dosing and Frequency

The dosage depends on the duration of use. For chronic conditions, such as arthritis, the IR form is typically dosed at 150 mg to 300 mg per day, divided into three or four doses. The ER form is taken 200 mg once daily. For acute, temporary needs, the IR form is taken as needed every 6 to 8 hours. The ER form is not recommended for acute pain.

Contextual and Population-Specific Rules

To facilitate intake, Dolgosin may be taken with food, milk, or antacids. Furthermore, adjustments are utilized for specific patient groups: Lower starting doses are typically initiated for older adults or small individuals. For patients with documented renal or hepatic impairment, the maximum daily dose is subject to reductions, with limits such as 100 mg/day in severe cases. The use of oral forms of Dolgosin has not been established in children under 18.

Research Evidence / Overview of Studies for Dolgosin

---

Evidence for Chronic Rheumatic Conditions (Osteoarthritis and Rheumatoid Arthritis)

Research into Dolgosin's role in conditions marked by functional limitations, such as osteoarthritis (OA) and rheumatoid arthritis (RA), is often summarized by Systematic Reviews and Meta-Analyses of Randomized Controlled Trials (RCTs). This high-level research consolidates findings from many individual studies that was evaluated in adult patients with confirmed diagnoses and was studied for fluctuating or unstable symptoms. Research examined outcomes related to physical discomfort, including measures like pain intensity, and patient-reported outcomes describing perceived discomfort related to daily functioning over defined time intervals.

The evidence base primarily focuses on outcomes related to physical discomfort over short to intermediate follow-up periods, typically ranging up to a few weeks. Long-term effects are not fully established, and there is limited information for long-term outcomes regarding disease progression or outcomes reflecting daily functioning over many years.

---

Evidence for Acute Pain and Inflammation (Dysmenorrhea, Trauma, and Post-Surgery)

Research into short-term symptom changes in acute settings—such as managing primary dysmenorrhea, pain following musculoskeletal trauma, or post-operative pain—relies heavily on short-course and single-dose Randomized Controlled Trials (RCTs). Research focused on episodes where symptoms become more noticeable and was evaluated in studies examining patient-reported outcomes describing perceived discomfort in acute settings. The outcomes describing episodic or acute changes were key, focusing on measures like pain intensity and the time elapsed until use of rescue medication was monitored.

Studies reported how symptoms evolved in the observed populations by measuring the proportion of participants whose pain intensity was at least 50% lower than baseline within a few hours. Data show patterns related to the time taken for the measured effect to occur and how long that effect was observed to last in the study setting. A key limitation is that these studies are predominantly designed for research exploring short-term symptom changes, often relying on single-dose trials with short follow-up durations.

---

What is Still Uncertain About Dolgosin Research

The research provides context, but it highlights several areas where data are still emerging or where the current evidence structure presents limitations. The evidence base remains focused on outcomes related to physical discomfort and short-term functional change, meaning that long-term effects are not fully established.

Across indications, the follow-up durations were limited, typically restricted to the acute episode or intermediate chronic treatment period. Furthermore, while meta-analyses summarize many studies, data for certain groups remain insufficient, meaning there is limited detailed information on how patients with specific comorbidities were observed in the pivotal trials. The research does not determine whether an individual will respond similarly; study results reflect the specific conditions under which they were conducted.

Key Studies & References Clinical use of ketoprofen lysine salt: a reappraisal in adolescents with acute respiratory infections

Common questions about Dolgosin (FAQ)

Q: How quickly should I feel the effects of Dolgosin?

Studies on the drug's absorption show that the concentration of the immediate-release form in the bloodstream typically peaks within 30 minutes to two hours after administration. This pharmacokinetic data provides context on the drug's absorption rate. The specific time that symptom relief is first noted can vary among individuals.

---

Q: Does Dolgosin cause drowsiness or make you tired?

Official safety information reports that drowsiness and fatigue have occurred as adverse reactions in some patients using this medication. Due to these potential effects, official information cautions against driving or operating machinery until a person knows how the medication affects them.

---

Q: Can Dolgosin affect my mood or anxiety levels?

Yes, regulatory documents note that the use of Dolgosin has been associated with effects on the central nervous system. These documented side effects include changes such as increased anxiety, depression, and confusion.

---

Q: Will taking Dolgosin make me sensitive to the sun?

Official warnings state that this medication can cause photosensitivity, which is an increased skin sensitivity to sunlight. Regulatory warnings indicate that precautions, such as using sun protection, may be necessary during treatment and following discontinuation.

---

Q: Is it normal to have a slight headache when starting Dolgosin?

Yes, according to official product information, a headache is listed among the common adverse reactions that people may experience when taking this medication.

---

Q: Are there any common foods or drinks to avoid while on Dolgosin?

Official labeling does not formally restrict specific foods, but it advises taking Dolgosin with food, milk, or antacids. Taking the drug with food, milk, or antacids is generally suggested for easing the potential for gastrointestinal irritation. Though food may slightly slow how quickly the medicine is absorbed, it does not change the total amount of drug that is eventually absorbed.

---

Q: Can Dolgosin cause stomach upset or nausea?

Yes, nausea, upset stomach, and abdominal pain are noted in official safety information as common adverse reactions associated with Dolgosin. Taking the medicine with food, milk, or antacids may be suggested to reduce the likelihood of these effects.

---

Q: Will I need to get blood tests while taking Dolgosin?

For some patients, monitoring may be required. Specifically, for individuals with pre-existing issues with their kidney or liver function, or those taking certain interacting medications, monitoring of organ function may be considered important for these patients, which often involves blood testing.

---

Q: How long does Dolgosin stay in your system after stopping it?

Official pharmacokinetic data indicates that the time it takes for half of the drug to be eliminated from the body (the half-life) is approximately 2 to 2.5 hours in most individuals. The body primarily eliminates the drug based on this half-life measurement.

---

Q: Are generic versions of Dolgosin available?

Yes, the active ingredient in Dolgosin, which is Ketoprofen, is widely available in generic formulations that are approved for use.

---

Q: Can Dolgosin cause weight changes?

Official reports on adverse effects list both weight gain and fluid retention (edema) as potential side effects associated with this medication.

---

Q: Are there different strengths or formulations of Dolgosin?

Yes, Dolgosin is available in different forms and strengths. These typically include immediate-release capsules, which come in multiple strengths (such as 25 mg, 50 mg, and 75 mg), and extended-release capsules, which are available in a 200 mg strength.

---

Q: Is it okay to drive or operate machinery while taking Dolgosin?

Due to the potential for dizziness, drowsiness, or blurred vision, official safety information cautions against driving or operating machinery until an individual is certain how the medication affects them.

---

Q: What should I do if a minor side effect of Dolgosin doesn't go away?

Regulatory advice suggests informing a healthcare provider or pharmacist promptly if any side effects, even minor ones, persist or seem to be getting worse.

---

Q: Is there a best time of day to take Dolgosin?

Official prescribing information indicates that the extended-release formulation is intended to be taken once daily and that maintaining a consistent timing each day is important for achieving steady drug levels. This timing ensures the drug works as intended over the course of the day.

---

Q: Are there any specific lifestyle changes recommended while taking Dolgosin?

Official warnings note that due to the increased risk of stomach bleeding associated with this medication, limiting or avoiding alcohol consumption may be necessary. Avoiding smoking is also a general caution.

---

Q: Does Dolgosin interfere with getting a good night's sleep?

Official product information notes that insomnia (difficulty sleeping) is listed as a common adverse reaction associated with the use of Dolgosin.

How to Store and Dispose of Dolgosin?

Regulatory documents outline specific storage and disposal requirements for Dolgosin (Ketoprofen) to maintain its stability and safety.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store oral forms at controlled room temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection	Keep the medicine away from direct light, excessive heat, and moisture.
Packaging	Store in the original, tightly closed, light-resistant container.
Child Safety	Mandatory to keep the product out of the reach of children.
Stability	For injectable solutions, discard product 28 days after the first opening.

Official Disposal Instructions

The FDA recommends that unused or expired Dolgosin be disposed of through a drug take-back program. If a program is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a bag, and then placed in the household trash. The medication must not be flushed down the sink or toilet.